What does the susceptible-dose dependent interpretive category for cefepime in ESBL-producing bacteria?

被引:2
作者
Menegucci, Thatiany Cevallos [1 ]
Bastos, Marina de Souza [1 ]
Viana, Giselle Fukita [1 ]
Brondani Moreira, Rafael Renato [1 ]
Garcia, Lourdes Botelho [1 ]
Cardoso, Celso Luiz [1 ]
Bronharo Tognim, Maria Cristina [1 ]
机构
[1] Univ Estadual Maringa, Dept Ciencias Basicas Saude, Maringa, Parana, Brazil
关键词
Cefepime; Minimum inhibitory concentration; Susceptible-dose dependent; Extended-spectrum beta-lactamase; Klebsiella pneumoniae; Enterobacter cloacae; SPECTRUM BETA-LACTAMASES; EXTENDED-SPECTRUM; INFECTIONS;
D O I
10.1080/1120009X.2015.1120407
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this study, we investigated the frequency of isolates included in the susceptible-dose dependent (SDD) category, according to the Clinical and Laboratory Standards Institute guidelines, carrying bla(TEM), bla(SHV) and bla(CTX) genes among 92 Klebsiella pneumoniae and 80 Enterobacter cloacae clinical isolates. The presence of one or more extended-spectrum beta-lactamases (ESBLs) genes was observed in 64% K. pneumoniae and 69% E. cloacae isolates. Nineteen isolates were included in SDD interpretive category criteria, of which 15 carried ESBL genes (seven K. pneumoniae and eight E. cloacae). Considering the high proportion of ESBL gene-containing isolates included in the SDD category (79%), we recommend that physicians exercise caution in the use of cefepime for treatment of infections caused by these isolates, reducing possible therapeutic failure, particularly in cases of ESBL-producing bacterial strains.
引用
收藏
页码:189 / 194
页数:6
相关论文
共 15 条
  • [1] [Anonymous], 2011, 24 INFORMATIONAL SUP
  • [2] [Anonymous], 2013, WAYNE PENNSYLVANIA C
  • [3] [Anonymous], M7A9 CLSI
  • [4] Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms
    Bhat, Sunil V.
    Peleg, Anton Y.
    Lodise, Thomas P., Jr.
    Shutt, Kathleen A.
    Capitano, Blair
    Potoski, Brian A.
    Paterson, David L.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (12) : 4390 - 4395
  • [5] Growing group of extended-spectrum β-lactamases:: The CTX-M enzymes
    Bonnet, R
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) : 1 - 14
  • [6] Clinical Laboratory Standards Institute, 2010, DOCUMENT M100S20
  • [7] Cefepime: a reappraisal in an era of increasing antimicrobial resistance
    Endimiani, Andrea
    Perez, Federico
    Bonomo, Robert A.
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2008, 6 (06) : 805 - 824
  • [8] European Committee on Antimicrobial Susceptibility Testing, 2014, BREAKP TABL INT MICS
  • [9] Cefepime Therapy for Monomicrobial Bacteremia Caused by Cefepime-Susceptible Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae: MIC Matters
    Lee, Nan-Yao
    Lee, Ching-Chi
    Huang, Wei-Han
    Tsui, Ko-Chung
    Hsueh, Po-Ren
    Ko, Wen-Chien
    [J]. CLINICAL INFECTIOUS DISEASES, 2013, 56 (04) : 488 - 495
  • [10] Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?
    Livermore, David M.
    Andrews, Jenny M.
    Hawkey, Peter M.
    Ho, Pak-Leung
    Keness, Yoram
    Doi, Yohei
    Paterson, David
    Woodford, Neil
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (07) : 1569 - 1577